Thanks to the $4 million raised through the Ice Bucket Challenge we were able to make significant strides in our work to find treatments for ALS. Here's what we invested in:

$2 million was invested in our Precision Medicine Program, allowing us to rapidly expand the program from 25 to 300 participants. The program now has 632 people enrolled.

$2 million was invested into anti-CD40L antibody development. Now called AT-1501, it entered a phase 1 clinical trial in November of 2018, making ALS TDI the first nonprofit biotech in any disease to develop a potential treatment and bring it from our own lab, through FDA review and into clinical trial.